ROG.SW
$322.30+1.60 (+0.50%)
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
Recent News
Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies
SRPT plans FDA filings to convert Amondys 45 and Vyondys 53 to full approvals, leveraging new data despite a missed endpoint in its confirmatory study.
Roche stops work on experimental SMA drug
In a letter to European patients, Roche said its decision to end development of “emugrobart” was based on the drug “not consistently” improving muscle growth and motor function in a key study.
Long-only funds are buying non-US stocks, BofA says
Investing.com -- Long-only investors shifted decisively toward non-U.S. equities in February, according to a new note from Bank of America.
Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?
ALNY's strong drug sales and advancing pipeline, including late-stage candidates, are driving momentum and supporting its long-term growth outlook.
Roche Bets Splits in Obesity Market Will Open Door to New Entrants
EXCLUSIVE: The pharmaceutical giant is re-entering the obesity market and aims to become a top-three player, rivaling the likes of Eli Lilly and Novo Nordisk.